Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT04255524
Starting soon Not applicable

Choroidal Change on OCTA in Eyes With High Myopia

NCT04255524 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Not applicable
Started
2020-02-01
Last updated
2020-02-05

Condition(s) studied

Myopia, ProgressiveChoroid Disease

Investigational drug(s) / intervention(s)

Optic coherence tomography angiography (OCTA)

Optic coherence tomography angiography (OCTA): Using non-invasive, repeatable, mature device OCTA to obtain choroidal angio-map

Study summary

Myopia is a global healthy concern, especially the high myopia and pathological myopia among Asian populations. However, its mechanism still remains largely unclear. Recent findings suggested choroidal changes might be related to the development of myopia. This study is to useOCT angiography (OCT-A) to investigate parapapillary choroidal microvasculature change in myopic eyes, and try to find the cause-and-effect relationship between choroidal change and the development of myopia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Spherical equivalent measurement can be included in above 4 groups 2. Willing to be followed up in the future 10 years Exclusion Criteria: 1. Deny to sign the patient consent, or deny to be followed 2. Evidence of cardiac, or diabetic, or CNS disease. 3. Clinically diagnosed with retinal or choroidal disease 4. Glucoma 5. Cataract or corneal disease that influence the quality of fundus OCTA image

Primary outcome measure(s)

  • Parapapillary choroidal microvasculature void (MvV) area — changes of MvV area from at 10 years
    area of parapapillary choroidal microvasculature void on OCTA images
  • Parapapillary choroidal microvasculature void (MvV) area — difference of MvV area in each group at baseline
    area of parapapillary choroidal microvasculature void on OCTA images
  • Parapapillary choroidal microvasculature void (MvV) area — changes of MvV area at 1 years
    area of parapapillary choroidal microvasculature void on OCTA images
  • Parapapillary choroidal microvasculature void (MvV) area — changes of MvV area at 3 years
    area of parapapillary choroidal microvasculature void on OCTA images
  • Parapapillary choroidal microvasculature void (MvV) area — changes of MvV area at 5 years
    area of parapapillary choroidal microvasculature void on OCTA images

Trial sites (1)

FacilityCityRegionStatus
First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu

More The First Affiliated Hospital with Nanjing Medical University trials in China

Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis Recruiting
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML Recruiting
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer Active, not recruiting
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC Starting soon
The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens Enrolling by invitation

Other trials for the same condition

Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses Enrolling by invitation
Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control Active, not recruiting
Myopia Progression With Freeform Myopia Control Spectacles Active, not recruiting
Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control Active, not recruiting
Evaluation of the Safety and Efficacy of the D.D.C Dual-control Technology Spectacle Lenses in Delaying the Progression of Myopia: a Randomized Controlled Trial Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04255524 on ClinicalTrials.gov ↗ ← All trials in China